Court triples Olden/Interpharm award to Ukraine's Ukrvaktsina to $60 million
This article was originally published in Scrip
The Oregon district court has updated its verdict in the Ukrvaktsina vs Olden Group/Interpharm case tripling to almost $60 million the payment that defenders should return to Ukraine's state budget. The court ruled on 20 May that Olden Group/Interpharm would return $19 million earned illegally through a drug price inflation fraud (scripintelligence.com, 31 May 2011).
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.